311 related articles for article (PubMed ID: 26993768)
1. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.
Norström MM; Rådestad E; Sundberg B; Mattsson J; Henningsohn L; Levitsky V; Uhlin M
Oncotarget; 2016 Apr; 7(17):23581-93. PubMed ID: 26993768
[TBL] [Abstract][Full Text] [Related]
2. [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].
Kramer G; Mitteregger D; Maj-Hes A; Sevchenco S; Brozek W
Urologe A; 2007 Sep; 46(9):1095-6. PubMed ID: 17671777
[No Abstract] [Full Text] [Related]
3. [Tumor infiltrating dendritic cells and Mucin1 gene expression in benign prostatic hyperplasia and prostate cancer].
Xiang ST; Zhou SW; Guan W; Wang QZ; Zhang B; Liu JH; Ye ZQ
Zhonghua Nan Ke Xue; 2003 Oct; 9(7):497-500. PubMed ID: 14628595
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate.
Elsässer-Beile U; Przytulski B; Gierschner D; Grussenmeyer T; Katzenwadel A; Leiber C; Deckart A; Wetterauer U
Prostate; 2000 Sep; 45(1):1-7. PubMed ID: 10960837
[TBL] [Abstract][Full Text] [Related]
5. Could inflammation be a key component in the progression of benign prostatic hyperplasia?
Kramer G; Marberger M
Curr Opin Urol; 2006 Jan; 16(1):25-9. PubMed ID: 16385197
[TBL] [Abstract][Full Text] [Related]
6. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
Kramer G; Mitteregger D; Marberger M
Eur Urol; 2007 May; 51(5):1202-16. PubMed ID: 17182170
[TBL] [Abstract][Full Text] [Related]
7. Proliferation of Prostate Stromal Cell Induced by Benign Prostatic Hyperplasia Epithelial Cell Stimulated With Trichomonas vaginalis via Crosstalk With Mast Cell.
Kim JH; Kim SS; Han IH; Sim S; Ahn MH; Ryu JS
Prostate; 2016 Nov; 76(15):1431-44. PubMed ID: 27325623
[TBL] [Abstract][Full Text] [Related]
8. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
Penna G; Mondaini N; Amuchastegui S; Degli Innocenti S; Carini M; Giubilei G; Fibbi B; Colli E; Maggi M; Adorini L
Eur Urol; 2007 Feb; 51(2):524-33; discussion 533. PubMed ID: 16905241
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
[TBL] [Abstract][Full Text] [Related]
11. The Differential Expression and Function of the Inflammatory Chemokine Receptor CXCR5 in Benign Prostatic Hyperplasia and Prostate Cancer.
Yang L; Gao L; Chen Y; Tang Z; Zhu Y; Han P; Li X; Wei Q
Int J Med Sci; 2015; 12(11):853-61. PubMed ID: 26640404
[TBL] [Abstract][Full Text] [Related]
12. Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study.
Torkko KC; Wilson RS; Smith EE; Kusek JW; van Bokhoven A; Lucia MS
J Urol; 2015 Aug; 194(2):454-61. PubMed ID: 25828974
[TBL] [Abstract][Full Text] [Related]
13. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
[TBL] [Abstract][Full Text] [Related]
14. Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia.
Liu Y; Zhao X; Sun X; Li Y; Wang Z; Jiang J; Han H; Shen W; Corrigan CJ; Sun Y
Prostate; 2015 Dec; 75(16):1844-56. PubMed ID: 26356122
[TBL] [Abstract][Full Text] [Related]
15. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
[TBL] [Abstract][Full Text] [Related]
16. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue.
Wu ZL; Yuan Y; Geng H; Xia SJ
Asian J Androl; 2012 Mar; 14(2):316-9. PubMed ID: 22157983
[TBL] [Abstract][Full Text] [Related]
17. Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.
Wong KK; Hussain FA; Loo SK; López JI
APMIS; 2017 Dec; 125(12):1092-1101. PubMed ID: 28972294
[TBL] [Abstract][Full Text] [Related]
18. The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.
Luna-Coronell JA; Vierlinger K; Gamperl M; Hofbauer J; Berger I; Weinhäusel A
Proteomics; 2016 Apr; 16(8):1204-14. PubMed ID: 27089054
[TBL] [Abstract][Full Text] [Related]
19. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.
Vignozzi L; Cellai I; Santi R; Lombardelli L; Morelli A; Comeglio P; Filippi S; Logiodice F; Carini M; Nesi G; Gacci M; Piccinni MP; Adorini L; Maggi M
J Endocrinol; 2012 Jul; 214(1):31-43. PubMed ID: 22562653
[TBL] [Abstract][Full Text] [Related]
20. Cellular senescence as a possible link between prostate diseases of the ageing male.
Fiard G; Stavrinides V; Chambers ES; Heavey S; Freeman A; Ball R; Akbar AN; Emberton M
Nat Rev Urol; 2021 Oct; 18(10):597-610. PubMed ID: 34294916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
